Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.69 +0.95 (+2.33%)
Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
Unheeding Markets ↗
Today oil prices rose over $70. 
Via Talk Markets
News headline image
Here's What Crushed Exelixis' Earnings ↗
R&D spending is hurting earnings, but long-term investors shouldn't be worried. 
Via The Motley Fool
News headline image
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
From Exelixis, Inc.
Via Business Wire
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
One is growing revenue. And the other may soon launch its first product. 
Via The Motley Fool
News headline image
3 Cheap Pharmaceutical Stocks to Grab Now ↗
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
News headline image
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Sterling At Five-Year High ↗
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
News headline image
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients ↗
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers OptiNose (NASDAQ:OPTN) stock rose... 
Via Benzinga
News headline image
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Is Exelixis a Buy? ↗
Revenue growth will probably accelerate soon, but it might not be enough. 
Via The Motley Fool
News headline image
What Investors Should Look for With Exelixis, DermTech, and Teladoc Health ↗
All three healthcare stocks could have solid growth prospects. 
Via The Motley Fool
News headline image
Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma? ↗
Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over. 
Via The Motley Fool
News headline image
Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript ↗
EXEL earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis: Q1 Earnings Insights ↗
Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year... 
Via Benzinga
News headline image
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
From Exelixis, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.